Thanks, Sandy.
disease, to which therapies disease, is XXX Turning now in Europe. zinc neuronal reduction the in are fatal that currently affects and to an do delay excellent an XXX disease no patients knockout a repression. months. protein around that prion production, animals year prevent approved typically Canada U.S. There disease-modifying XX a can and and get Prion for reduction prion We or approximately fit disease XX awful exist. also prion Prion finger prevents in is not prion disease. the disease, know
therefore, expression progression of that or prion disease the halt We, neurodegeneration. may and believe repression slow
delivery given progresses. disease, achieve we We brain the spreads as brain the misfolded widespread knew to for that disease that the to prion wanted protein prion throughout
finger As to mentioned capsid nonhuman and X our earlier, identified repressor separate it newly zinc therefore prion-targeted packaged the intravenously we primates. into administer STAC-BBB
which animals one STAC-BBB one to assess level to location animal expressed. prion-targeted prion-targeted much brain and these illustrates XXX the brain of collected and of the row The from measured. Each we order was of how bunches that measure each the the analysis we finger that each the zinc to, regions expression on conducted X was delivers of In dot RT-qPCR represents images was finger of color punches collected, dosed. represents zinc
intensity the that all of key data levels the X of STAC-BBB As expression green one ZFR of see brain the zinc protein animals. prion-targeted mediated in finger wide for the from support right, GFP are indicated top punches. by the consistent you and results expression confirmed each can repressor in expression These
correlated see quantify We we reduction expression brain mRNA were if expression regions a analyzed. brain that an to prion punches. with reduction We of all wanted in prion XX associated in to these in next happy
well. such bulk the we expressed are oligodendrocytes, is as of at prion the have data level in and consist moment, in you seen but the cell As the reduction the percent total prion at brain astrocytes reduction the microglia. upwards cell single we not Cells I at seeing neurons here as a higher. similar will past, studies XX%, tau show when Because in multiple in When punches of neurons, brain cell reminder, brain these a level. reduction of to must do solely additional brain XX% XX% of including types individual individual be types, neuron looking analysis significantly
how collaboration on these model So we impact with gene, prion-infected Institute, around the mice now XXX Broad prion mouse of can In see target this finger in a as aggressive will prion administered just concluded disease, in progression. repressors days the that the that zinc prion untreated level in repression level to mouse and think bar of engineered saw we single zinc die green dose extend you bulk we can disease a animals. observed repressor of or survival any we do days the the in post graph consistently Based finger significantly intervention, following mice, infection.
Without either clearly, XXX infection. XX repression
of progressed, later treatments of compared X, to were single These starting showed in which be shown a a progression.
In only X, time there is at approximately in graph was to to in lifespan extension point XX a data in ASOs an living evaluated the post as incredible after finger study, shown in to illustrated graphic However, same lifespan. infection when minimal post those required was a a as And beyond this mouse notable is induce on disease separate model. that prion treated the show multiple further with administered an extension zinc ASOs normal infection alteration mouse. infection, days extended within able This of lifespan. mice control or the from disease when graph published were survival animals is also XXX repressor administration in XXX days performance
that which what in believe the dose dose to disease showing reflect A considered and Conversely, vg XXX still the higher, progression even time mid-dose XeXX that's able of data in was kilogram infection which zinc level, delay we have These aligned the repressor a decide single dose per shown potential of we a more appropriate. is will graph profoundly to we mice. see should line when administered post we days the that finger extend survival AAV, clinic. is X, in to
progressing meaningful zinc prion finger showed with in and in potency, The with both vivo. XX% cell, greater and targets detectable that no prion program lead is clinical per our reduction than off represser vitro
We quarter expect in a enabling anticipate submitting half U.K. prion for year of studies the this to the clinical begin trial XXXX. second of and clinical fourth application in toxicology in the
the from function tau, of tauopathies. stabilization tau, data treatment ASO seems cognitive cement Recent study Biogen's Alzheimer's neurodegenerative which Moving called with diseases now for to implication injections to of disease. regular of target a shows tau's addressing well-known ASOs in
finger also dementia progressive supranuclear are XX account medical zinc address that a than there with need including span palsy, indications, of that tauopathies host could disorders addition, In distinct more a unmet large and frontotemporal with a for high our population we approach. very potentially patient
IV primates. indications, ability Using brain with delivery to in a with nonhuman to reach ability combination of capsid's disease telepathy regions various given potential high a all demonstrate see tau STAC-BBB onetime the for capabilities a progression in administration the to halt zinc the finger ability specificity repressor the we
the administered to in repressor, the finger intravenously throughout detectable and here, of we and vitro.
Into which of brain. per XeXX, XeXX doses, different on our X and slide zinc our kilo. tau saw packaged genomes we we shows clinical finger Here, for lead targets at tau off capsid XeXX prion, exceptionally Similar no are tested specific STAC-BBB repressor widespread expression fantastic zinc vector the repression before looking expression
dose indicating also a of higher and finger to see the dose-dependent as intensity the were expression. pleased level increased, with assessing we very increasing the X expression green zinc dose we're of Here, levels,
of to finger but repression. zinc levels Importantly, also the and the only corresponding prion expression similarly at study, we are looking the of tau not level
deep lateral tau astrocytes cells. is also the tau brain it are the these a know that expressed only of show disease on that and not critical oligodendrocytes. in for neurons in is We in we data these is so geniculate Here, focused nucleus. prion, pathology, region, we the repressing neurons, but Like gene driver is thalamic and which expression including why
uses promoter. the case, construct clinical this In a synapsin lead
finger with dose-dependent zinc expression. expression to pleased of So to we tau expression in neurons. that finger zinc know increase are correlated targeting that a decrease see dose-dependent a only We were we
Like consists not neurons. whole of a of in the cell just prion bulk experiment, this types, many brain is punches, analysis which
So to we of be in cell neurons. at achieving the single able level to must this higher be achieve level, at the tau level bulk repression significantly repression
see we of illustrated level lateral above correlated you'll at reduction in geniculate in higher dose we proportion in same achieved staining from image by of at the see almost in bulk an dark the the is GFP region nucleus, tau neurons study. Here, the top in which the XX% the likely as the brain the the arms region to that this and
Let's closely a brain key at of take the progressive called pons part a in look telepathy supranuclear brain moment palsy. and to the region the more stem
single analysis, and left tau the utilized in correlation is of brain increased neurons. for the region. tissue at activity between approach to previous understanding zinc what zinc punch dose-dependent this we analysis I on scope bulk And showed tissue in ZFR the important, a expression a a like finger you the is expression bulk expression and cell immunohistochemistry the decreased multiplexed so Because and slide, saw level to addition tau also finger repression On the in we the RNA visualize manner.
of This beautiful a data at allowing only on single the is recently what's us detail high level going and cell level. understand is possible, shows that to
the a with image top the an clinical control is the express bottom robustly animals in repressor. dose finger neurons, see of are this the the control the tau white.
Conversely, region, resulted clearly lead reduction bottom purple In STAC-BBB of row XX% top zinc encoding is that express in of in animal shown approximately which in we mRNA images, zinc complete pons cells. fingers tau the the repression tau calculate animal, striking in treated was and from corresponding where finger tau. the saw can of On almost green, that neurons the We expressed zinc in in those you which of
motor our power zinc more together the data Here, of this we in single tau this finger the both in show cell and of demonstrating beautiful instance working cortex. repressor STAC-BBB
within particular, brain expressed clearly the and Orange. neurons vehicle top see where in the On glia row, purple, you and in mRNA the tau control across was region,
Here, different was levels no the mRNA consistent remain detected tau and the images. zinc repressor between finger
finger see a finger left. great expression, our panel. finger This green, we the right the data of Zooming a more neurons.
And at little indicated elimination into the zinc of and the gives and mRNA, across single us a zinc in almost mRNA truly saw we we of promise complete repressor Conversely, hope this is that the for administration in tau in most where STAC-BBB repressor. particularly bottom, the encouraging detected importantly, as saw bottom middle an potent repression the on zinc of in we image visible image, the tau tau
making program, For finger a program to into potential our ourselves lead identified clinical suited tau activities partner. have and well zinc clinic either advanced, are this with or well we IND-enabling the the move
studies submission Toxicology of the early as the IND XXXX. quarter potential early could be second quarter a as year initiated as as this with fourth of
a way as a using how approach. we're through lead Finally, indication, the program I'll outline portfolio NavX.X to balance this diversified delivery our and neurology
not STAC-BBB, clinic. does but program known is capsid the AAV instead NavX.X already delivery uses that in a Our leverage
susceptive to of a channel here address. patient a large voltage-gated in new a reducing chronic capable in expressed this very as the an pain there neuropathic treat we dorsal transmission space believe critical pain potently we of a is play the was to By medicine potentially host mutations and and this reaching can in NavX.X of no signals pain root aim need role in urgent in Our DRG, order perception. population and develop sodium is channel to indications.
There NavX.X prevent for therapies other the ganglia a
to very motivated neuropathy. with moving with small on fiber and focus are NavX.X be initially we plan to program patients forward our So
the targeting data levels you clinical from as at we the see level. of sodium finger enclose saw these lot NavX.X SCNXA, NavX.X molecules because impacting here, without a lead zinc use of meaningful to repressor our similarities channels a a As preclinical share exquisite protein repression of with difficult other small channels.
It's repression only to structural in vitro channels that treat demonstrated any gene specificity Nav
level, zinc to well finger DNA are makes they them However, suited which at technology. the distinct, the
Taking the the and blood-brain targeting of this to DRG see column barrier. the left, a outside spinal you the neurons into cells in study groups animal models on
of see of mRNA red. zinc the shown repressor the finger in resulted gene SCNXA of knockdown the expression, potent you absence NavX.X injection intrathecal elimination expression, which of in This in by mice, which significant the we Using indicated observed at complete almost light, then a an the level.
If zinc repressor as very these and the are called you a of nerve results blue, in induce have pain.
The pain that you a impressive. the surgery spared red bars intrathecally perception full the finger look repressor resulted understand injury gold injection are bottom the the reversal orange animals received neuropathic pain single at zinc those middle to a is pain, dark can the mouse of in model. of use after the mouse standard performed finger to pain, very indicated and the model indicated administration our of single what in nerves similar middle by looks this cut in which which We in as never the of animals model like
and study right, on we saw NavX.X. Finally, repression intrathecally SCNXA. DRG dose-dependent that In you doses potent potent achieve study, can we fingers primate the the repression nonhuman show of target different the X administered and to and see far we of wanted we of zinc the where
as publications seek toxicity, anything toxicity. And there's identifying lot research DRG clinic. any into crucial we would emphasis find Importantly, the of a and advance studies not be such is which program indicative peer-reviewed these did this that of we about to potential in
we to program, We encouraged forward studies. completing look and by are very these final the NavX.X toxicology
to of this open will to in Sandy year.
I We expect quarter the this we for hand now up fourth for before this back an to Q&A. wrap program IND submit
